Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Coherus Oncology, Inc. CHRS

Healthcare  —  Biotechnology
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

Register an account and get your Powerpack now or Login
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio 0.97 5.11 0.00 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡
P/S ratio 3.94 5.99 1.15 3.13 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
P/FCF ratio 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡
P/Operating CF (8.44) 5.53 (22.85) (6.61) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
P/B ratio 2.73 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
Price to Tangible BV 11.26 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales 4.89 17.89 2.55 4.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
EV/EBITDA 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡
EV/Operating CF (1.49) (23.09) (3.75) (3.92) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
EV/FCF (1.48) (22.08) (3.73) (3.88) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
Quick Ratio 1.36 0.88 1.14 2.17 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Current Ratio 1.47 1.21 1.43 2.75 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Debt/EBITDA 0.76 (0.71) (1.78) (1.12) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Debt/Assets 14.34% 59.07% 75.19% 98.86% ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Debt/Equity 0.61 (2.01) (2.45) (3.46) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Asset Turnover 0.12 0.05 0.46 0.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Operating CF/Net income (0.82) (0.72) 0.74 0.83 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capex/Depreciation 0.00 0.00 (0.08) (0.55) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Depreciation/Fixed assets 2.92 2.05 0.74 0.42 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Interest Coverage 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
ROE (473.47%) (17.52%) 143.81% 1,470.09% ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
ROA 47.54% 5.29% (42.85%) (50.29%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
ROIC 0.00% (1,795.44%) (78.30%) (109.76%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡
Cash ROIC (51.76%) (8.89%) (45.26%) (47.18%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Return on Tangible Assets 248.32% 46.60% (159.68%) (116.10%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Accounts Receivable Turnover 0.60 0.14 1.39 1.81 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡‡‡
Accounts Payable Turnover 0.72 0.27 6.80 5.06 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡
Inventory Turnover 3.74 0.26 3.14 1.83 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — —
Average Days of Receivables 159.41 1,692.07 369.65 190.18 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡‡‡
Average Days of Payables 261.98 1,190.15 80.85 60.03 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡
Days of Inventory on Hand 83.81 175.95 143.72 202.03 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — —
Research and Development Expense of Revenue 258.20% 348.00% 42.54% 94.46% ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Selling, General and Administrative Expense of Revenue 238.56% 475.51% 74.64% 94.05% ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Intangible Assets out of Total Assets 0.18 0.12 0.11 0.01 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Share Based Compensation of Revenue 40.23% 105.35% 16.76% 24.04% ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Graham Net Nets 0.06 (1.51) (1.17) (0.36) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
Graham Number 4.14 0.00 10.90 12.24 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡
Earnings Yield 102.82% 19.57% (81.85%) (44.18%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
Free Cash Flow Yield (83.84%) (13.53%) (59.47%) (36.81%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
Revenue per Share 0.36 0.23 2.73 2.72 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Operating CF per Share (1.18) (0.18) (1.86) (3.11) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capex per Share 0.00 0.00 0.00 (0.03) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Free Cash Flow per Share (1.18) (0.18) (1.86) (3.13) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash per Share 1.47 1.10 1.25 2.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shareholders Equity per Share 0.52 (1.15) (2.05) (1.77) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Interest Debt per Share 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book value per Share 0.52 (1.15) (2.05) (1.77) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Free Cash Flow (138.51) (20.44) (175.17) (243.16) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Working Capital 66.32 58.60 143.86 242.54 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Capital Expenditures — — (0.29) (2.04) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Current Asset Value 9.38 (238.94) (347.40) (237.03) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Receivables 70.38 191.43 185.24 116.49 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — — ‡‡‡‡‡
Average Payables 19.19 31.84 23.37 13.84 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Inventory 3.69 33.41 50.70 38.22 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — —
Average Assets 353.44 539.07 555.23 580.09 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Average Common Equity (35.49) (162.71) (165.42) (19.85) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/EBIT 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡
Capex to Sales 0.00 0.00 0.00 0.01 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Profit Margin 398.43% 108.03% (92.48%) (138.24%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Price to Operating Income 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡ ‡‡‡